PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches

Journal of Thoracic Disease

article

Ranya Barayan¹  Xiaozhuo Ran²  Benjamin H. Lok¹ 

[1] Institute of Medical Science, Faculty of Medicine, University of Toronto;Radiation Medicine Program, Princess Margaret Cancer Centre;Department of Medical Biophysics;Department of Radiation Oncology, University of Toronto

关键词: Small cell lung cancer (SCLC);    poly (ADP-ribose) polymerase inhibitors (PARPi);    chemotherapy;    radiation sensitizer;    immunotherapy;   

DOI  :  10.21037/jtd.2020.03.89

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Small cell lung cancer (SCLC) is a very aggressive, highly lethal, neuroendocrine tumor that constitutes 15% of all lung cancer cases. It is characterized by its rapid disease progression and high relapse rate leading to poor survival for diagnosed patients. Recently, poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a novel therapeutic strategy for SCLC. Preclinical studies have demonstrated that PARPi possesses cytotoxic activity as a single-agent and in combination with other anti-cancer agents. Predictive biomarkers of response to PARPi, such as SLFN11, have also been described in SCLC. This review aims to summarize the recent preclinical investigations and the relevant clinical trials that evaluate PARPi in SCLC. Here, we highlight the potential role of PARPi in a biomarker-selected manner and in combination with chemotherapy, targeted agents, radiotherapy and immunotherapy.

【 授权许可】

Unknown